Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...

Semzuvolimab is under clinical development by United BioPharma and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS).

There is no cure for atopic dermatitis (eczema), but there are treatments that can help manage this common inflammatory skin condition. Regardless of the stage of the disease, self-care is important ...

The U.S. Food and Drug Administration has approved Organon's Vtama (tapinarof) 1% cream for an additional indication -- the topical treatment of atopic dermatitis in adult and pediatric patients ...

Atopic dermatitis, which many people call eczema, and contact dermatitis are often confused due to their similar symptoms. However, a person inherits atopic dermatitis, while contact dermatitis ...

A rash may occur after you contract HIV. It commonly appears on the face and chest but can also appear in other places. Medications used to treat HIV as well as certain infections may also cause ...

Red, dry, itchy skin is a tell-tale sign of one of the most common—and most irritating—skin conditions: eczema. And although flare-ups can happen all year long, they tend to get worse in ...

NEW YORK, NY — For immediate control of a hand eczema flare, the old soak and smear approach with moisturizers or corticosteroids might live on, but they are moving to the back of the shelf for ...

LONDON, Dec 17 (Reuters) - A new long-acting preventive HIV drug could reach the world’s poorest countries by the end of 2025 or early 2026, a global health official told Reuters on Tuesday.

截止到2024年，全球人类免疫缺陷病毒（HIV）防治工作已取得令人鼓舞的进展，但仍存在部分问题。《柳叶刀》（The Lancet）发表的社论指出，目前2030年消除HIV对公共卫生威胁的可持续发展目标仍未步入正轨，艾滋病大流行继续在一些人群中蔓延，并且侵犯人权 ...

The Department of Health and Human Services allocated at least $73.9 million in grant funding to programs aimed at either mitigating the alleged harm racism causes minorities living with HIV or ...

Dec. 17, 2024 -- The FDA last week approved Nemluvio for treating moderate to severe atopic dermatitis, a type of eczema, in people aged 12 or older. Nemluvio is to be used with topical ...